Results 121 to 130 of about 99,201 (311)

Ambulatory mediastinal biopsy for hematologic malignancies

, 1997
Objective: We retrospectively evaluated our experience with outpatient surgical biopsy of mediastinal lesions in patients with hematologic malignancies, its cost-effectivness and ability to allow diagnosis.
C. Ricci, DE GIACOMO, Tiziano, VENUTA, Federico, RENDINA, Erino Angelo, E. O. Pescarmona, I. Flaishman, E. Guarino   +6 more
core   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study from the EUSTAR Cohort

Arthritis Care &Research, Accepted Article.
Objective JAK inhibitors (JAKis) have shown promising effects in early‐phase studies of SSc. We aimed to assess the safety and explore effectiveness of JAKis compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the EUSTAR cohort was performed.
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P Denton, Madelon C Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Review of advances in CAR-T therapies in malignant hematology

Frontiers in Oncology
There have been numerous advancements in immune cell effector therapies in the malignant hematology space. This review article explores the pivotal studies that led to the approval of chimeric antigen receptor T-cell (CAR-T) therapies for hematologic ...
Neda Amirmokhtari, Neda Amirmokhtari, Forat Lutfi, Forat Lutfi   +3 more
doaj   +1 more source

Laparoscopic splenectomy in patients with hematologic malignancies.

, 1999
BACKGROUND: Although laparoscopic splenectomy (LS) for benign hematologic disease is well accepted, its role in hematologic malignancies is not clearly defined. This study examined the efficacy and feasibility of LS for hematologic malignancies. METHODS:
Berman, R S, Feig, B W, Sweeney, J F, Kumparatana, M, Yahanda, Alan M, MD, FACS, Mansfield, P F, Leroux, B, Hemmila, M R, Porter, G A, Pollock, R E   +9 more
core  

An ontology for representing hematologic malignancies: the cancer cell ontology

, 2019
Background Within the cancer domain, ontologies play an important role in the integration and annotation of data in order to support numerous biomedical tools and applications.
Lucas M. Serra, Alexander D. Diehl, William D. Duncan   +2 more
core   +2 more sources

The B7 Homologues and their Receptors in Hematologic Malignancies [PDF]

, 2012
The B7 homologues and their receptors regulate both peripheral tolerance and adaptive immunity. This field is rapidly evolving as new ligands and receptors are being identified.
Zou, Weiping, Wilcox, Ryan A., Chen, Lieping, Ansell, Stephen M., Lim, Megan S.   +4 more
core   +1 more source

Functional Precision Oncology Approach Using Nanoliter Droplet Array for Drug Sensitivity Testing in Lung Cancer

Advanced Healthcare Materials, EarlyView.
A miniaturized drug sensitivity and resistance testing (DSRT) workflow based on the Droplet Microarray (DMA) platform enables functional drug testing using minimal patient‐derived tumor material. By screening nanoliter‐scale droplets containing as few as 300 cells, this approach generates reproducible and tumor‐specific drug response profiles ...
Maryam Salarian, Vicky L. Schiling, Thomas Muley, Michael Allgäuer, Florian Eichhorn, Michael Meister, Marc A. Schneider, Anna A. Popova   +7 more
wiley   +1 more source

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

Journal of Hematology & Oncology, 2018
Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, Yubin Kang   +7 more
doaj   +1 more source

Hematologic malignancies [PDF]

Current Opinion in Hematology, 1999
openaire   +5 more sources

Spatiotemporal Sequential Delivery of Chidamide Regulates Macrophage Reprogramming in Lymphoma Microenvironment Through HDACs‐STAT3 Pathway

Advanced Science, EarlyView.
Our study identifies the HDACs‐STAT3 axis as key regulator for M2 macrophage accumulation in DLBCL. We developed Chid@M2pep‐EVs/TP, a pH‐responsive drug delivery system for M2 macrophage specific chidamide administration. By coupling M2‐targeted chidamide with EVs‐mediated delivery, this system reprograms M2 to M1 via HDAC inhibition and STAT3 ...
Bo Dai, Shuo Wang, Xiaotong Peng, Kunpeng Wu, Mengyao Wu, Zhaoning Lu, Haoshu Zhong, Xiaohan Qian, Shuiyi Tan, Hui Yang, Tanlezi Sun, Jing Wang, Jie Zhang, Hua Jiang, Yin Tong, Tong Chen   +15 more
wiley   +1 more source